Presentation is loading. Please wait.

Presentation is loading. Please wait.

Stephen A. Deppen, PhD, Jeffrey D. Blume, PhD, Melinda C

Published byBruce Flynn Modified over 5 years ago

Similar presentations

Presentation on theme: "Stephen A. Deppen, PhD, Jeffrey D. Blume, PhD, Melinda C"— Presentation transcript:

1 Predicting Lung Cancer Prior to Surgical Resection in Patients with Lung Nodules 
Stephen A. Deppen, PhD, Jeffrey D. Blume, PhD, Melinda C. Aldrich, PhD, MPH, Sarah A. Fletcher, BA, Pierre P. Massion, MD, Ronald C. Walker, MD, Heidi C. Chen, PhD, Theodore Speroff, PhD, Catherine A. Degesys, MD, Rhonda Pinkerman, NP, Eric S. Lambright, MD, Jonathan C. Nesbitt, MD, Joe B. Putnam, MD, Eric L. Grogan, MD, MPH  Journal of Thoracic Oncology  Volume 9, Issue 10, Pages (October 2014) DOI: /JTO Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Consort diagram of VUMC and Tennessee Valley Healthcare System VA cohort. VUMC, Vanderbilt University Medical Center cohort; VA, Veteran Affairs; NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Comparison of AUC for the Mayo Clinic model using originally published estimates and TREAT model in the VUMC and VA cohorts. CIs for AUC are reported for each estimate model. TREAT model AUC is significantly higher compared with the Mayo Clinic model in each cohort (p < 0.001). AUC, area under the receiver operating curve; TREAT, Thoracic Research Evaluation And Treatment; VA, Veteran Affairs; VUMC, Vanderbilt University Medical Center cohort; CI, confidence interval. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Box plots comparing Brier score from 500 bootstrap samples of the data for each model and from each cohort. Brier score for the TREAT model exhibited better calibration of predicted probability of lung cancer when compared with the Mayo Clinic model in the VUMC cohort (TREAT = 0.12 versus Mayo Clinic = 0.17) and VA cohort (TREAT = 0.07 versus Mayo Clinic 0.18). Brier score values of 0.25 are the same as a chance and lower values of Brier score represent increased calibration of the model. As Brier score decreases from 0.25 to 0, the predicted probability of cancer increasingly equals the observed probability of cancer and the calibration is improved. TREAT, Thoracic Research Evaluation And Treatment; VUMC, Vanderbilt University Medical Center cohort; VA, Veteran Affairs. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Stephen A. Deppen, PhD, Jeffrey D. Blume, PhD, Melinda C"

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer  Babatunde A. Yerokun, MD, Chi-Fu.

A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer  Babatunde A. Yerokun, MD, Chi-Fu.
Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience  Debra P. Ritzwoller, PhD, Nikki.

Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience  Debra P. Ritzwoller, PhD, Nikki.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.
Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A

Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.
Surgical Treatment in Patient with Non–Small-Cell Lung Cancer with Fissure Involvement: Anatomical versus Nonanatomical Resection  Giovanni Leuzzi, MD,

Surgical Treatment in Patient with Non–Small-Cell Lung Cancer with Fissure Involvement: Anatomical versus Nonanatomical Resection  Giovanni Leuzzi, MD,
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer?  Traves D. Crabtree, MD, Varun Puri,

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer?  Traves D. Crabtree, MD, Varun Puri,
A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed.

A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed.
Existing General Population Models Inaccurately Predict Lung Cancer Risk in Patients Referred for Surgical Evaluation  James M. Isbell, MD, MSCI, Stephen.

Existing General Population Models Inaccurately Predict Lung Cancer Risk in Patients Referred for Surgical Evaluation  James M. Isbell, MD, MSCI, Stephen.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 

Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 
Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H

Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers

Similar presentations

Ads by Google